• PXR Activation, Liver Regeneration, and CYP Activity

  2026-09-28

  Bi et al. show that activating pregnane X receptor with pregnenolone-16α-carbonitrile in rats links liver enlargement and regeneration with increased CYP3A1/2 and CYP2C6/11 activity. The work is important because it evaluates both hepatic structure and functional drug metabolism, including after two-thirds partial hepatectomy.

• PID1 and Cholesterol Metabolism in Tumor Macrophages

  2026-09-28

  This paper examines how PID1 relates to cholesterol handling and macrophage state in tumors. Its reported findings connect myeloid PID1 deficiency with altered LDL uptake, cholesterol oxidation products and macrophage signaling, using human tumor data and preclinical models.

• CTP for Translational mRNA: From IVT to p21 Therapy

  2026-09-27

  How CTP supports in vitro mRNA synthesis—and what a bladder cancer p21 mRNA-LNP study teaches translational teams about connecting reagent quality, experimental control, and localized delivery.

• CGP 55845 Hydrochloride for Reliable Assays

  2026-09-26

  Learn how CGP 55845 hydrochloride (SKU B5086) can help researchers isolate GABAB receptor-dependent effects in neurotransmission and cell-based experiments. This scenario-driven guide covers assay design, concentration interpretation, solution handling, and the limits of applying a receptor antagonist to viability readouts.

• Prestained Protein Marker: F4005 Workflow Guide

  2026-09-25

  Practical guidance for interpreting protein blots alongside cell viability, proliferation, and cytotoxicity assays. Learn how APExBIO SKU F4005 supports size verification and workflow compatibility without confusing a protein marker with a direct measure of cell viability.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-09-25

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for experiments examining renin-angiotensin system activity and related cardiovascular or renal endpoints. Use it in an established RAS workflow with appropriate vehicle controls; it is not a general-purpose peptide for unrelated signaling studies, and the product dossier does not specify assay concentrations or potency.

• AmpliFold Capture-and-Release Boosts LFA Sensitivity

  2026-09-24

  The AmpliFold strategy uses a cleavable capture step followed by release and high-affinity rebinding to address kinetic limits in lateral flow assays. In a HER2 model, it improved sensitivity by up to 16-fold in selected configurations, including detection with large nanoparticles in buffer and human serum.

• Capecitabine Assays: Activation or Resistance?

  2026-09-24

  Capecitabine response in a tumor model can reflect both cellular sensitivity and the model’s capacity to activate this prodrug. This article connects capecitabine pharmacology with patient-derived gastric cancer assembloid findings to help researchers distinguish those effects when designing preclinical assays.

• CCT007093: A PPM1D Inhibitor for P38 Studies

  2026-09-23

  Use CCT007093 to test how PPM1D/WIP1 restrains P38 signaling, from renal tubular pyroptosis models to cancer-cell assays. Its value is strongest in a controlled workflow that pairs pathway readouts with viability, genetic, and inhibitor-rescue controls.

• FDA Library Screening Finds Four MERS-CoV Inhibitors

  2026-09-23

  De Wilde and colleagues screened an FDA-approved compound library and identified chloroquine, chlorpromazine, loperamide, and lopinavir as low-micromolar inhibitors of MERS-CoV replication in cell culture. The study established a practical repurposing framework, while also showing why cellular activity must be followed by exposure, mechanism, animal, and clinical validation.

• Interpreting In Vitro Cancer Drug Responses

  2026-09-22

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves assay design, time-course interpretation, and evaluation of anti-cancer compounds in cancer research.

• Rice 5hmC Maps Reveal Context-Dependent Drought Control

  2026-09-22

  A 2025 rice study combines ACE-seq with optimized Tn5mC-seq to produce a single-base map of 5-hydroxymethylcytosine during drought and rehydration. Its findings show that 5hmC is a low-abundance, dynamic mark whose effect on transcription depends on whether it occurs in promoters, gene bodies, or other genomic compartments.

• Capecitabine and the Tumor–Stroma Response

  2026-09-21

  Capecitabine offers translational researchers more than a fluoropyrimidine prodrug: its activation biology can expose how tumor–stroma interactions reshape chemotherapy response. Patient-derived gastric assembloids provide a practical framework for testing that hypothesis.

• HotStart 2X Green qPCR Master Mix for Epigenetics

  2026-09-21

  Discover how HotStart 2X Green qPCR Master Mix can support targeted validation of RNA-seq findings in histone-acetylation and spermatogenesis research. This article connects assay chemistry with biological interpretation, helping researchers distinguish transcript changes from altered cell composition and protein-level phenotypes.

• Proximity Labeling Tracks Synaptic Protein Trafficking

  2026-09-20

  Pascual-Caro and de Juan-Sanz developed a synaptic-cleft proximity-labeling strategy that captures endogenous proteins transiently exposed during synaptic vesicle exocytosis. By matching the biotinylation pulse to rapid vesicle cycling, the method enables activity-dependent proteomic analysis and provides direct evidence for trafficking of ATG9A and NPTX1.

652 records 1/44 page Next 12345 下5页 Last page